The authors conclude that radiotherapy combined with intratumoral administration of IL-2 in patients with late-stage NPC is a novel and effective treatment for this aggressive malignancy.

patients must be hospitalized for high-dose systemic pre-chemotherapy and post-conditioning interleukin-2 (IL-2) treatment, which causes severe toxicity and mortality. TILT Biotherapeutics has ...

that are typically associated with wild-type IL-2 treatment. Furthermore, the ability of STK-009 to provide an IL-2 signal exclusively to SYNCAR-001 cells may allow us to bypass the need for ...

Coya Therapeutics (NASDAQ:COYA) shares tumbled 23% Tuesday after the company reported mixed results from a Phase 2 clinical ...